Oral dabigatran etexilate versus enoxaparin for venous thromboembolism prevention after total hip arthroplasty: pooled analysis of two phase 3 randomized trials

Bengt I. Eriksson1*, Ola E. Dahl2,3, Nadia Rosencher4, Andreas Clemens5,6, Stefan Hantel7, Martin Feuring5,8, Jörg Kreuzer5,8, Michael Huo9 and Richard J. Friedman10

Abstract

Background: Two phase 3 trials compared 28–35 days of treatment with oral dabigatran 220 mg or 150 mg (RE-NOVATE) or 220 mg (RE-NOVATE II) once daily with subcutaneous enoxaparin 40 mg once daily for prevention of venous thromboembolism (VTE) after elective total hip arthroplasty.

Methods: This prespecified pooled analysis compared the outcomes for the dabigatran 220 mg dose with enoxaparin, which included 4,374 patients. Total VTE (venographic and symptomatic) plus all-cause mortality (primary efficacy), major VTE (proximal deep vein thrombosis [DVT] or non-fatal pulmonary embolism) plus VTE-related death, and bleeding events were evaluated. Efficacy analysis was based on the modified intention-to-treat (ITT) population and safety analysis was based on all treated patients. The common risk difference (RD) for dabigatran versus enoxaparin was estimated using a fixed effects model.

Results: Total VTE and all-cause mortality occurred in 6.8 % (114/1,672) and 7.7 % (129/1,682) (RD: −0.8 %, 95 % confidence interval [CI] −2.6 to 0.9) for dabigatran and enoxaparin, respectively. Major VTE plus VTE-related mortality occurred in 2.7 % (46/1,714) and 4.0 % (69/1,711) (RD: −1.4 %, 95 % CI −2.6 to −0.2) of patients receiving dabigatran 220 mg and enoxaparin, respectively. Major bleeding occurred in 1.7 % (37/2,156) and 1.3 % (27/2,157) (RD: 0.5 %, 95 % CI −0.2 to 1.2) for dabigatran and enoxaparin respectively.

Conclusions: Extended prophylaxis with oral dabigatran 220 mg once daily was as effective as enoxaparin 40 mg once daily in reducing the risk of total VTE and all-cause mortality after total hip arthroplasty, with a similar bleeding profile. The clinically relevant outcome of major VTE and VTE-related death was significantly reduced with dabigatran versus enoxaparin.

Trial registration: NCT00657150 and NCT00168818

Keywords: Arthroplasty, Bleeding, Enoxaparin, Dabigatran, Deep vein thrombosis, Mortality, Prophylaxis, Pulmonary embolism, Venous thromboembolism
Background
Dabigatran etexilate (hereafter referred to as dabigatran) is an orally administered direct, reversible thrombin inhibitor for the prevention and treatment of various thromboembolic disorders. Two previously reported phase 3 trials (RE-NOVATE and RE-NOVATE II) [1, 2] compared the efficacy and safety of dabigatran (220 mg or 150 mg once daily, started 1–4 h after surgery) with enoxaparin (40 mg once daily, started at least 12 h before surgery) for the prevention of venous thromboembolism (VTE) and all-cause mortality after elective total hip arthroplasty. In both of these studies, the non-inferiority of dabigatran 220 mg over enoxaparin 40 mg for the primary efficacy endpoint, total VTE (the composite of symptomatic and asymptomatic venographic deep vein thrombosis [DVT], non-fatal pulmonary embolism [PE]) plus all-cause mortality, was demonstrated. Bleeding and adverse event (AE) rates with dabigatran were low and similar to those reported for enoxaparin. Dabigatran 220 mg once daily (starting with a half dose 1–4 h after the end of surgery) is now approved in more than 100 countries for thromboprophylaxis in patients undergoing total hip arthroplasty.

The prespecified pooled analysis of these two studies was planned to compare the effect of dabigatran 220 mg and enoxaparin 40 mg once daily on the primary efficacy endpoint of total VTE and all-cause mortality in patients undergoing total hip arthroplasty.

Methods
Study design and setting
RE-NOVATE and RE-NOVATE II were prospective, double-blind, double-dummy, randomized, multicentre, non-inferiority studies. Participants were adults aged at least 18 years who were scheduled for primary elective total hip arthroplasty. The two trials had identical study eligibility criteria and were designed to be as similar as possible. Briefly, patients were randomized to treatment with oral dabigatran 220 mg or 150 mg once daily (the latter dose was not used in RE-NOVATE II), or subcutaneous enoxaparin 40 mg once daily started the evening before surgery; in some countries enoxaparin treatment was started postoperatively in accordance with local practice.

The first dose of dabigatran was halved and given 1–4 h after wound closure, provided clinical assessment of perioperative and postoperative bleeding and drainage indicated adequate hemostasis. If administration was delayed until the day after surgery, a full dose was given, followed by a second dose at least 12 h later. Treatment was continued until mandatory bilateral venography at 28–35 days. In both trials, the treatment period was defined as the time from first dose to 3 days after the last dose. Continued VTE prophylaxis was at the discretion of the treating physician. Patients attended a clinical follow-up visit 3 months after surgery. Concomitant administration of low dose aspirin (<160 mg) and selective cycloxygenase-2 inhibitors was allowed during treatment. Elastic compression stockings were permitted, but intermittent pneumatic compression devices were prohibited.

Both studies were approved by National Independent Ethics Committees and conducted according to the Declaration of Helsinki (October 1996 version). All patients gave signed informed consent prior to entry.

Outcome measures
The prespecified primary efficacy endpoint of this pooled analysis was identical with that of the individual trials, i.e., the composite of total VTE and all-cause mortality. The endpoint was analyzed in the modified intention-to-treat (mITT) population, comprising all randomized and treated patients who underwent elective total hip arthroplasty and had evaluable adjudicated data on VTE (venographic confirmation in both legs or symptomatic event) or died during the treatment period. The main secondary efficacy outcome was the composite of major VTE (venographic or asymptomatic proximal DVT and/or PE) and VTE-related mortality during treatment. Additional predefined secondary efficacy outcomes during the treatment period included total DVT (venographic or asymptomatic), proximal DVT (venographic or symptomatic), and symptomatic DVT and/or PE.

All efficacy endpoints were based on assessments made by the same blinded Independent Venous Thromboembolic Event Adjudication Committee. Mandatory bilateral venography was performed within 24 h of the last oral dose, as described previously [3]. Suspected symptomatic DVT during treatment or follow-up was confirmed by ultrasound or venography. Symptoms suggestive of PE mandated confirmation by ventilation-perfusion scintigraphy, pulmonary angiography or spiral chest computer tomography, depending on local center preference. Deaths were considered related to VTE if they were categorized as “VTE related” or “unexplained” by the Independent Adjudication Committee.

All randomized patients who received at least one dose of study treatment were evaluable for safety. The main safety endpoint was the frequency of major bleeding events (which, different to previously performed studies, also included bleeding from the surgery wound site) occurring between intake of the first dose of study medication and 3 days after the last dose. Secondary safety outcomes included the composite of major and clinically relevant non-major bleeding events, any bleeding events during treatment, liver enzyme elevations (≥3 x the upper limit of the normal reference range [ULN] for serum alanine aminotransferase [ALT]) and acute
coronary events (defined as confirmed unstable angina, myocardial infarction [MI], and cardiac death). This is in line with a number of pooled analyses from total knee and hip replacement trials with dabigatran, which included more than 8,000 patients [4, 5]. Major, clinically relevant, non-major and minor bleeding events were defined according to accepted guidelines [6], as reported previously [3]. In particular, the definition of major bleeding includes wound site bleeding events, in accordance with recommended guidelines [6]. ALT elevations ≥3 x ULN and any suspected acute coronary syndrome events were reviewed by an Independent Committee who were blinded to treatment allocation. An assessment of causality was provided for each of the reviewed patient cases.

**Statistical analysis**

The statistical analysis plan described here was planned before commencement of the RE-NOVATE II trial in accordance with regulatory recommendations [7].

For each trial, the difference in the proportion of patients with an event (efficacy or safety) was compared between dabigatran 220 mg and enoxaparin 40 mg as a risk difference (RD) as this was considered the most clinically meaningful measure. A common RD estimate across the two trials was calculated using a fixed-effects model (maximum likelihood estimation) [8], based on inverse variance weights for combined results from the individual trials, and compared with results obtained with a random effects model (DerSimonian and Laird method). The RD was not expected to differ between

---

**Fig. 1** Flow of patients through the study
the studies. Heterogeneity of the common RD between the studies was assessed using Cochran’s $\chi^2$ and the $I^2$ statistic; $p < 0.10$ was considered to denote statistically significant heterogeneity and where $I^2$ was greater than 50 %, heterogeneity was considered substantial [9]. Pooled event rate data for each treatment group are presented alongside the common RD results obtained from the pooled analysis.

Subgroup analyses were planned to investigate the influence of age, body weight, gender, and renal function (determined from calculated baseline creatinine clearance) on the incidence of the primary efficacy outcome, as well as bleeding events. For these comparisons the odds ratio and 95 % confidence intervals (CIs) for the analyzed subgroups were calculated using a fixed-effects model for the efficacy and safety endpoints.

Sensitivity analyses were conducted to explore the robustness of the results. The impact of missing or non-evaluable venography data, based on imputation of missing values using best and worst case scenarios (all treatment success or all treatment failure), was investigated to ensure that missing data did not affect the

Table 1 Demographic and baseline characteristics

|                           | Dabigatran 220 mg | Enoxaparin 40 mg |
|---------------------------|-------------------|-----------------|
|                           | (n = 2,156)       | (n = 2,157)     |
| Number of treated patients| 2,156             | 2,157           |
| Age, yr                   | 63 ± 11           | 63 ± 11         |
| Females, n (%)            | 1177 (54.6)       | 1152 (53.4)     |
| Weight, kg                | 79 ± 16           | 79 ± 16         |
| Body mass index<sup>a</sup> | 27.8 ± 4.7      | 27.6 ± 4.6      |
| Previous VTE, n (%)       | 65 (3.0)          | 54 (2.5)        |
| Creatinine clearance<sup>b</sup>, mL/min | 92 ± 31          | 93 ± 31         |
| Race<sup>c</sup>, n (%)   |                   |                 |
| White                     | 2,051 (95.1)      | 2,052 (95.1)    |
| Asian                     | 96 (4.4)          | 88 (4.1)        |
| Black                     | 5 (0.2)           | 12 (0.6)        |
| Other                     | 4 (0.2)           | 5 (0.2)         |
| Geographical region, n (%)|                   |                 |
| Western Europe            | 1,282 (59.5)      | 1,291 (59.9)    |
| Central Europe            | 474 (22.0)        | 470 (21.8)      |
| North America             | 170 (7.9)         | 168 (7.8)       |
| India                     | 91 (9.0)          | 88 (4.1)        |
| Australia/New Zealand/South Africa | 139 (6.4) | 140 (6.5) |
| Patients treated and operated, n (%) | 2,138 (99.2) | 2,134 (98.9) |
| Anesthesia<sup>d</sup>, n (%) |                       |                 |
| General alone             | 525 (24.4)        | 503 (22.3)      |
| Neuraxial alone<sup>e</sup> | 1,461 (67.8)    | 1,486 (65.8)    |
| Combination<sup>f</sup>   | 149 (6.9)         | 144 (6.4)       |
| Mean duration of surgery ± SD, min | 85.4 ± 30.2 | 85. ±30.4 |

Study treatment

Mean time to first subcutaneous injection<sup>g,h</sup> in relation to surgery, hr: $-15.6 ± 20.7$ vs. $-15.2 ± 13.5$.

Mean time to first oral dose postsurgery<sup>h</sup>, hr: $3.1 ± 2.6$ vs. $3.2 ± 2.7$.

Median (range) duration of hospital stay, d: $8.5 (3–51)$ vs. $8.5 (3–26)$.

Median (range) treatment duration, d: $31.6 (1–89)$ vs. $31.7 (1–49)$.

Data are given as mean ± SD except where indicated

SD standard deviation, VTE Venous thromboembolism

*Body mass index was defined as weight in kilograms divided by square of height in meters; *Creatinine clearance rates were calculated using the Cockcroft–Gault formula; *As reported by the investigator; *Patients may have had more than one type of anesthetic; *Includes spinal and epidural anesthesia; *Peripheral nerve block plus general or neuraxial anesthesia; *26 patients in RE-NOVATE II group received their first dose postsurgery; *Includes both active treatment and placebo; *Time from surgery until day of discharge, data available in RE-NOVATE for 1,136 and 1,140 patients, respectively
power of the trial or bias any estimation of the treatment effect.

Results
Study population
A total of 4,374 patients were randomized across 20 countries between December 2004 and May 2009, of whom 4,313 were treated and therefore evaluable for safety. 4,272 patients were operated upon and treated with oral dabigatran 220 mg ($n = 2,138$) or subcutaneous enoxaparin 40 mg ($n = 2,134$) (Fig. 1). A further 918 (21.5 %) patients were excluded from the mITT population, as usual in all studies with venography, mainly because bilateral venography was not performed (usually declined by the patient) or the venograms were considered indeterminate by the venography adjudication committee. This percentage is consistent with that reported in contemporary studies using venography as an end-point [3, 10, 11]. In total, 240 (11.2 %) patients allocated dabigatran and 230 (10.7 %) allocated enoxaparin discontinued treatment. The primary reasons for discontinuation were similar between groups. The two groups were well balanced in terms of demographic and surgical characteristics (Table 1).

Efficacy outcomes
Efficacy outcomes are summarized in Table 2. The primary outcome (the composite of total VTE and all-cause mortality) occurred in 114 (6.8 %) patients treated with dabigatran 220 mg and 129 (7.7 %) treated with enoxaparin 40 mg (RD: −0.8 %, 95 % CI −2.6 to 0.9; $p = 0.35$). Distal (below knee) DVT detected by venography was the most frequent component of the primary endpoint. There were four deaths during treatment; three in the dabigatran group (one related to VTE), and one in the enoxaparin group not related to VTE.

The main secondary outcome (composite of major VTE and VTE-related mortality) occurred in 2.7 % with dabigatran versus 4.0 % with enoxaparin (RD: −1.4 %, 95 % CI −2.6 to −0.2; $p = 0.03$). Symptomatic DVT occurred in 0.3 % versus 0.2 % ($p = 1.00$), respectively. Over the whole 3-month (treatment plus follow-up) study period the rate of symptomatic VTE plus all-cause mortality was 0.9 % in each treatment group.

There was a significant difference in the risk for proximal DVT (venographic or symptomatic) for dabigatran versus enoxaparin (RD: −1.4 %, 95 % CI −2.6 to −0.3; $p = 0.02$). No difference in total DVT (venographic or symptomatic) (RD: −1.1 %, 95 % CI −2.7 to 0.6; $p = 0.22$) was observed. The incidence of symptomatic DVT and

### Table 2  Efficacy outcomes, modified ITT population. Data are given as n/N (%)

| Outcome | Dabigatran 220 mg | Enoxaparin 40 mg | Risk difference vs. enoxaparin, % (95 % CI)$^a$ | p value |
|---------|-------------------|-----------------|-----------------------------------------------|--------|
| Total VTE and all-cause mortality | | | | |
| Pooled data | 114/1,672 (6.8) | 129/1,683 (7.7) | −0.8 (−2.6, 0.9) | 0.35 |
| RE-NOVATE | 53/880 (6.0) | 60/897 (6.7) | −0.7 (−2.9, 1.6) | |
| RE-NOVATE II | 61/792 (7.7) | 69/786 (8.8) | −1.1 (−3.8, 1.6) | |
| Major VTE$^b$ and VTE-related mortality$^c$ | | | | |
| Pooled data | 46/1,714 (2.7) | 69/1,712 (4.0) | −1.4 (−2.6, −0.2) | 0.03 |
| RE-NOVATE | 28/909 (3.1) | 36/917 (3.9) | −0.8 (−2.5, 0.8) | |
| RE-NOVATE II | 18/805 (2.2) | 33/795 (4.2) | −1.9 (−3.6, −0.2) | |
| Symptomatic events | | | | |
| Symptomatic VTE$^d$ | 17/2,138 (0.8) | 16/2,134 (0.7) | | |
| Symptomatic DVT | 6/2,138 (0.3) | 5/2,134 (0.2) | | 1.00 |
| Symptomatic PE | 6/2,138 (0.3) | 5/2,134 (0.2) | | |
| Death | 3/2,138 (0.1) | 1/2,134 (0.0) | | 0.62 |
| Total asymptomatic DVT | 100/1,665 (6.0) | 122/1,677 (7.3) | | |
| Proximal | 35/1,709 (2.0) | 63/1,706 (3.7) | | |
| Distal only | 65/1,666 (3.9) | 59/1,679 (3.5) | | |
| Total study period (treatment + follow-up) | | | | |
| Symptomatic VTE + all-cause mortality | 18/2,048 (0.9) | 19/2,059 (0.9) | | 0.09 |

N = number of patients included within each population with percentage in parentheses
CI confidence interval, DVT deep vein thrombosis, ITT intention-to-treat, PE pulmonary embolism, VTE venous thromboembolism
$^a$Based on normal approximation of binomial distribution for single trial and the fixed effects approach using a weighted average (inverse variance) for pooled analyses; $^b$Major VTE was defined as venographic and symptomatic proximal DVT and/or non-fatal PE; $^c$VTE-related mortality included fatal PE and deaths where VTE cannot be excluded; $^d$Includes any symptomatic DVT (proximal or distal) and non-fatal or fatal symptomatic PE in patients in the safety population who had undergone surgery
PE during treatment was comparable across treatments ($p = 1.0$) (Table 2). Similar results were reported for the main secondary outcome.

Bleeding-related outcomes are summarized in Table 3. There was no difference in major bleeding rates between the two groups; 37 (1.7 %) with dabigatran versus 27 (1.3 %) with enoxaparin (RD: 0.5 %, 95 % CI –0.2 to 1.2; $p = 0.19$). Only one fatal bleeding event in the dabigatran group was reported. Of the 37 major bleeding events with dabigatran, 19 (51.4 %) occurred before any active study drug had been administered. In contrast, all bleeding events in the enoxaparin group occurred after the first dose, which was given preoperatively in 94 % of patients. Similarly, there was no difference between the groups in the rate of major or non-major clinically relevant bleeding events (5.0 % versus 4.0 % dabigatran and enoxaparin, respectively, $p = 0.13$), overall bleeding rates or the requirement for blood transfusion.

### Subgroup analyses
Treatment with dabigatran resulted in consistent reductions in the primary outcome irrespective of age (<65, 65–75, >75 years, $p = 0.05$), weight ($\leq 70$, >70–90, >90 kg) ($p = 0.50$), gender ($p = 0.54$) or renal function (calculated creatinine clearance $>80$, 50–80, $<50$ mL/min at baseline, $p = 0.32$). There were no differences in the primary outcome across additional subgroups according to treatment (Fig. 2).

The results remained robust in sensitivity analyses (data not shown), indicating that missing venography data did not bias any estimation of the treatment effect. There were no differences between results obtained using the fixed versus random effects model.

### Adverse events
The AE profile of each treatment was similar (Table 4). Postoperative wound infection was reported as an AE in 37 patients, 16 (0.7 %) in the dabigatran group and 21 (1.0 %) in the enoxaparin group. AEs leading to treatment discontinuation occurred in 6.2 % and 5.5 % of the dabigatran and enoxaparin groups, respectively (Table 4). Less than 1 % of patients in either group had an adjudicated MI or ischemic stroke during or after treatment. Fifteen patients (8 [0.4 %] in the dabigatran group and 7 [0.3 %] in the enoxaparin group) had cardiovascular events (defined as ischemic stroke or MI) after >3 days off study drug.

Moderate liver enzyme elevation (ALT levels >3 x ULN) at any time after baseline occurred in 3.4 % of the dabigatran group and 5.5 % of the enoxaparin group (Table 4). In three patients in the dabigatran group, there was an associated two-fold increase in bilirubin

---

### Table 3  Bleeding-related outcomes, safety population

| Outcome                                      | Dabigatran 220 mg (n = 2,156) | Enoxaparin (n = 2,157) | Risk difference vs. enoxaparin, % (95 % CI) | $p$ value |
|----------------------------------------------|-------------------------------|------------------------|---------------------------------------------|-----------|
| **Bleeding Events**                          |                               |                        |                                             |           |
| Major, Total no. patients, % (95 % CI)$^a$    | 37 (1.7, 1.2-2.4 %)           | 27 (1.3, 0.8-1.8 %)    | 0.5 % (–0.2, 1.2)                           | 0.20      |
| Fatal                                        | 1 (0.05)                      | 0 (0)                  |                                             |           |
| In a critical organ                          | 2 (0.1)                       | 0 (0)                  |                                             |           |
| Clinically overt associated with 20 g/L or more fall in hemoglobin | 31 (1.4)                      | 19 (0.9)               |                                             |           |
| Clinically overt leading to transfusion of two or more units of packed cells or whole blood | 33 (1.5)                      | 22 (1.0)               |                                             |           |
| Warranting treatment cessation               | 1 (0.05)                      | 1 (0.05)               |                                             |           |
| Leading to re-operation                      | 2 (0.1)                       | 3 (0.1)                |                                             |           |
| **Onset of events – No. events/total no. patients (%)** |                               |                        |                                             |           |
| Before the first oral dose                   | 19/37 (51.4)                  | 10/28 (35.7)           |                                             |           |
| After the first oral dose                    | 18/37 (48.6)                  | 18/28 (64.3)           |                                             |           |
| Clinically relevant non-major bleeding       | 71 (3.3)                      | 60 (2.8)               |                                             |           |
| Major or clinically relevant non-major bleeding | 108 (5.0)                    | 87 (4.0)               | 1.0 % (–0.3, 2.2)                           | 0.13      |
| Minor bleeding                               | 131 (6.1)                     | 128 (5.9)              |                                             |           |
| Any bleeding events                          | 239 (11.1)                    | 215 (10.0)             |                                             |           |
| Patients receiving blood transfusions - n/N (%) | 858/2,138 (40.1)             | 880/2,134 (41.2)        |                                             |           |

Data are given as number (%) of patients except where indicated

CI confidence interval

$^a$Patients may have been included in more than one category
Table 2 Total VTE and all-cause mortality during treatment period by subgroup (risk differences)

| Geographical region       | Event incidence/N | Risk difference (%) (95% CI) |
|---------------------------|-------------------|-----------------------------|
| North America             | 9/141             | -0.3 (-6.2, 5.5)            |
| Western Europe            | 48/990            | -1.0 (-3.0, 1.0)            |
| Eastern Europe            | 30/359            | -1.6 (-5.8, 2.5)            |
| India                     | 14/75             | 5.0 (-6.9, 16.8)            |
| Other                     | 13/107            | -1.9 (-11.0, 7.3)           |

| Weight [kg]               | Event incidence/N | Risk difference (%) (95% CI) |
|---------------------------|-------------------|-----------------------------|
| <50                       | 1/29              | -3.7 (-15.3, 7.9)           |
| 50-100                    | 108/1580          | -0.9 (-2.7, 0.9)            |
| >110                      | 5/60              | -2.1 (-7.2, 11.3)           |

| Creatinine clearance [ml/min] | Event incidence/N | Risk difference (%) (95% CI) |
|-------------------------------|-------------------|-----------------------------|
| <25                           | 32/494            | -2.3 (-5.6, 1.1)            |
| 25-40                         | 55/741            | -0.3 (-3.0, 2.4)            |
| >40                           | 19/226            | -1.0 (-4.6, 2.6)            |

| BMI [kg/m²]                  | Event incidence/N | Risk difference (%) (95% CI) |
|-------------------------------|-------------------|-----------------------------|
| <25                           | 55/805            | 0.2 (-2.3, 2.6)             |
| 25-30                         | 58/867            | -1.8 (-4.3, 0.7)            |

| Gender                       | Event incidence/N | Risk difference (%) (95% CI) |
|-------------------------------|-------------------|-----------------------------|
| Male                          | 55/805            | 0.2 (-2.3, 2.6)             |
| Female                        | 59/867            | -1.8 (-4.3, 0.7)            |

| Age [years]                  | Event incidence/N | Risk difference (%) (95% CI) |
|-------------------------------|-------------------|-----------------------------|
| <65                           | 53/668            | -0.2 (-2.4, 2.1)            |
| 65-75                         | 47/610            | -0.5 (-3.5, 2.6)            |
| >75                           | 14/194            | -5.6 (-11.7, 0.5)           |

| Geographical region       | Event incidence/N | Risk difference (%) (95% CI) |
|---------------------------|-------------------|-----------------------------|
| North America             | 81/1190           | 0.3 (-1.7, 2.2)             |
| Western Europe            | 33/462            | -3.8 (-7.4, -0.2)           |
| Eastern Europe            | 107/1596          | -0.7 (-2.5, 1.0)            |
| India                     | 7/76              | -5.1 (-16.3, 6.2)           |

Discussion

The prespecified pooled analysis of these two studies was planned to compare the effect of dabigatran 220 mg and enoxaparin 40 mg once daily on the primary efficacy endpoint of total VTE and all-cause mortality in patients undergoing total hip arthroplasty. This pooled analysis of data from ~4,300 patients undergoing elective total hip arthroplasty in the two RE-NOVATE studies adds to the evidence base for dabigatran for prevention of thromboembolic complications.

Dabigatran 220 mg was as effective as enoxaparin 40 mg in decreasing the risk of VTE and all-cause mortality at 5 weeks. These results were consistent across age, weight, gender, or creatinine clearance subgroups. It is notable that the rate of major VTE and VTE-related death was significantly lower with dabigatran (p = 0.03), with a 1.4% absolute reduction in risk versus enoxaparin. This rate compares with the absolute reduction (0.7% to 1.7%) observed in studies with the oral FXa inhibitors (apixaban and rivaroxaban) versus enoxaparin in patients undergoing hip arthroplasty and receiving prophylaxis for an equivalent extended duration [10, 11]. Thus, dabigatran may have similar benefits in reducing more clinically relevant, proximally located lower limb thrombi as other available oral anticoagulants.

The risk of bleeding was similar to that for enoxaparin. Bleeding rates (major, clinically relevant non-major, and minor bleeding) did not differ statistically between dabigatran and enoxaparin across the two studies. All but 33% of the major bleeding events were reported to have occurred after day 3, although the onset of bleeding could have started earlier.

Taken together, these results indicate that dabigatran is a useful prophylactic therapy in this clinical setting. By pooling the data from the two studies, a higher grade of elevation. None of these cases met the criteria (Hy's law) for severe drug-induced hepatotoxicity [12].
Table 4 Adverse events, safety population

| Outcome                                | Dabigatran 220 mg (n = 2,156) | Enoxaparin 40 mg (n = 2,157) |
|----------------------------------------|-------------------------------|-----------------------------|
| Total with AEs                         | 1,563 (72.5)                 | 1,588 (73.6)                |
| Serious AEs                            | 146 (6.8)                    | 141 (6.5)                   |
| AEs leading to treatment discontinuation | 134 (6.2)                    | 118 (5.5)                   |
| Drug-related AEs (investigator evaluation) | 191 (8.9)                    | 199 (9.2)                   |
| Wound infections\(^a\)                 | 16 (0.7)                     | 21 (1.0)                    |
| Cardiovascular events                  |                              |                             |
| Myocardial infarction                  | 2 (<0.1)\(^b\)              | 6 (0.3)                     |
| Ischemic stroke                        | 0                            | 1 (0.1)                     |
| ALT elevation; no. (%) patients        |                              |                             |
| >3 x ULN anytime post baseline         | 71/2,101 (3.4)\(^c\)         | 115/2,097 (5.5)\(^c\)      |
| >3 x ULN plus bilirubin >2 x ULN during treatment period | 3/2,092 (0.1)\(^d\)         | 0/2,096                     |

Data are given as number (%) of patients except where indicated.

\(^a\) AE adverse event, ALT alanine aminotransferase; CI: confidence interval; DVT: deep vein thrombosis; ITT: intention-to-treat; MI: myocardial infarction; mITT: modified intention-to-treat; PE: pulmonary embolism; RD: risk difference; ULN: upper limit of normal reference range; VTE: venous thromboembolism.

Conclusions

In conclusion, this pooled analysis of two trials comparing dabigatran with enoxaparin demonstrated that dabigatran was comparable to enoxaparin in preventing total VTE and all-cause mortality when used for the same duration, with a similar risk of bleeding and AEs. In clinical practice, dabigatran can be considered an attractive thromboprophylaxis in patients undergoing elective hip arthroplasty, with potential economic advantages.

Abbreviations

ALT: alanine aminotransferase; CI: confidence interval; DVT: deep vein thrombosis; ITT: intention-to-treat; MI: myocardial infarction; mITT: modified intention-to-treat; PE: pulmonary embolism; RD: risk difference; ULN: upper limit of the normal reference range; VTE: venous thromboembolism.

Competing interests

Bengt I Eriksson has received fees as a consultant or speaker for Astellas, Bayer, Boehringer Ingelheim, Daiichi Sankyo and Takeda. Nadia Rosencher has received fees as consultant or speaker for Aspen, Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, Boehringer Ingelheim and Sanofi. Ola E Dahl has been a scientific consultant for AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline and Sanofi-Aventis. Richard J Friedman has received fees as a consultant for Johnson & Johnson, Astellas and Boehringer Ingelheim, and is on the speaker’s bureau for Sanofi-Aventis. Michael H Huo has received fees as a consultant for Biomet, DePuy, Koycera, Pfizer, Janssen, AO Foundation and Zimmer. Andreas Clemens was an employee of Boehringer Ingelheim and is a current employee at Novartis Pharma. Stefan Hartel, Jörg Kreuzer and Martin Feuring are employees of Boehringer Ingelheim.

Authors’ contributions

All authors were involved in the study design and/or the collection, analysis and interpretation of data, in writing the report, and the decision to submit for publication. All authors read and approved the final manuscript.

Acknowledgements

All trials were sponsored by Boehringer Ingelheim (BI). This work was supported by BI. The authors received no compensation related to the development of the manuscript. Dr. Vanessa Lane provided editorial assistance, with funding from BI.

Author details

\(^1\)Department of Orthopaedics, Sahlgrenska University Hospital, SE 413 45 Gothenburg, Sweden. \(^2\)Thrombosis Research Institute, Emmanuel Kaye Building, Marnese Road, London, UK. \(^3\)Innlandet Hospital Trust, Brumunddal,
References

1. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370:949–56.

2. Eriksson BI, Dahl OE, Hsiung V, Kurth AA, Hantel S, Hermanson K, et al. Oral dabigatran etexilate versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011;105:721–9.

3. Eriksson BI, Dahl OE, Buller HR, Hettiarachchi R, Rosencher N, Bravo ML, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005;3:103–11.

4. Friedman RJ, Dahl OE, Rosencher N, Caprini JA, Kurth AA, Francis CW, et al. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res. 2010;126:175–82.

5. Eriksson BI, Smith JJ, Caprini J, Hantel S, Clemens A, Feuring M, et al. Evaluation of the acute coronary syndrome safety profile of dabigatran etexilate in patients undergoing major orthopedic surgery: findings from four Phase 3 trials. Thromb Res. 2012;130:396–402.

6. The European Agency for the Evaluation of Medicinal Products. Guideline on clinical investigation of medicinal products for prophylaxis of high intra- and post-operative venous thromboembolic risk. CPMP/ EWP/707/98 Rev. 1. 2007. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/05/WC500143764.pdf. Accessed 30 June 2015.

7. The European Agency for the Evaluation of Medicinal Products. Points to consider on application with 1. meta-analyses; 2. one pivotal study. CPMP/EWP/ 2330/99. 2001. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003657.pdf. Accessed 30 June 2015.

8. Normand SL. Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med. 1999;18:321–59.

9. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.

10. Eriksson BI, Borts LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;359:2765–75.

11. Lassen MR, Gallus A, Roskob GE, Pineo G, Chen D, Ramirez LM. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363:2487–98.

12. U.S. Food and Drug Administration. Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation. http://www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ucm174090.pdf. Accessed 30 June, 2015.

13. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:85S–45S.

14. Friedman RJ, Gallus AS, Cusner FD, FitzGerald G, Anderson Jr FA. Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin. 2008;24:87–97.

15. Wolowacz SE, Roskell NS, Maciver F, Beard SM, Robinson PA, Plumb JM, et al. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. Clin Ther. 2009;31:194–212.

16. Fernandes RA, Quintella FF, Teich VD. Cost-effectiveness analysis of dabigatran etexilate versus enoxaparin for the prevention of venous thromboembolism after total hip replacement under the Brazilian public health care system perspective [abstract]. Value Health. 2009;12(7):A502.

17. Boersma C, Kappelhoff BS, Postma MJ. Dabigatran etexilate is cost-saving for the primary prevention of venous thromboembolic events following major orthopedic surgery in the Netherlands [abstract]. Value Health. 2009;12(7):A334.